HDAC9 and acute lymphoblastic leukemia: In contrast to their lack of specific sensitivity to HDAC inhibitors, the three childhood ALL cell lines with the MEF2D-HNRNPUL1 fusion demonstrated uniquely potent and specific sensitivity to bryostatin-1 relative to other BCP-ALL cell lines (P = 6.5e-06).